Henlius Bevacizumab Trials Results Get International Recognition

As Company Submits HLX04 For Approval In China

China’s Henlius has received international recognition of Phase I and III clinical trial results for its bevacizumab biosimilar, HLX04, providing “strong evidence for the efficacy and safety similarity between HLX04 and the reference bevacizumab.” The company has submitted its NDA for the product to the NMPA for various indications.

China Pharma
Henlius seeks approval for its bevacizumab biosimilar in China • Source: Alamy

Shanghai Henlius Biotech Co. Ltd.has announced that results of Phase I and III clinical trials for its bevacizumab biosimilar, HLX04, have been published in two internationally well-known journals, Cancer Chemotherapy and Pharmacology and BioDrugs, providing “strong evidence for the efficacy and safety similarity between HLX04 and the reference bevacizumab,” Avastin.

Henlius has also confirmed the submission of its new drug application for HLX04 to China’s National Medical Products Administration for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.